Biohaven Pharmaceutical Holding Stock Today
| BHVN Stock | USD 36.00 3.12 7.98% |
Performance0 of 100
| Odds Of DistressLess than 14
|
Biohaven Pharmaceutical is selling at 36.00 as of the 19th of December 2024; that is 7.98 percent decrease since the beginning of the trading day. The stock's open price was 39.12. Biohaven Pharmaceutical has less than a 14 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 30th of December 2022 and ending today, the 19th of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 23rd of September 2022 | Category Healthcare | Classification Health Care |
Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. Biohaven Ltd. is a subsidiary of Biohaven Pharmaceutical Holding Company Ltd. The company has 101.12 M outstanding shares of which 7.84 M shares are currently shorted by private and institutional investors with about 9.66 trading days to cover. More on Biohaven Pharmaceutical Holding
Moving against Biohaven Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Biohaven Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chairman | Vlad Coric | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NYSE Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsBiohaven Pharmaceutical can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Biohaven Pharmaceutical's financial leverage. It provides some insight into what part of Biohaven Pharmaceutical's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Biohaven Pharmaceutical Holding (BHVN) is traded on New York Stock Exchange in USA. It is located in 215 Church Street, New Haven, CT, United States, 06510 and employs 239 people. Biohaven Pharmaceutical is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.96 B. Biohaven Pharmaceutical conducts business under Biotechnology sector and is part of Health Care industry. The entity has 101.12 M outstanding shares of which 7.84 M shares are currently shorted by private and institutional investors with about 9.66 trading days to cover.
Biohaven Pharmaceutical Holding currently holds about 23.21 M in cash with (331.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.48.
Check Biohaven Pharmaceutical Probability Of Bankruptcy
Ownership AllocationBiohaven Pharmaceutical holds a total of 101.12 Million outstanding shares. The majority of Biohaven Pharmaceutical Holding outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Biohaven Pharmaceutical to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Biohaven Pharmaceutical. Please pay attention to any change in the institutional holdings of Biohaven Pharmaceutical Holding as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Biohaven Ownership Details
Biohaven Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Citadel Advisors Llc | 2024-09-30 | 1.8 M | |
| Geode Capital Management, Llc | 2024-09-30 | 1.7 M | |
| Point72 Asset Management, L.p. | 2024-09-30 | 1.5 M | |
| Perceptive Advisors Llc | 2024-09-30 | 1.5 M | |
| Adage Capital Partners Gp Llc | 2024-09-30 | 1.5 M | |
| Armistice Capital, Llc | 2024-09-30 | 1.2 M | |
| Redmile Group, Llc | 2024-09-30 | 1 M | |
| Schmeidler A R & Co Inc | 2024-09-30 | 1 M | |
| Brown Advisory Holdings Inc | 2024-09-30 | 968.4 K | |
| Vanguard Group Inc | 2024-09-30 | 7.8 M | |
| Stifel Financial Corp | 2024-09-30 | 6.5 M |
Biohaven Pharmaceutical Historical Income Statement
Biohaven Stock Against Markets
Biohaven Pharmaceutical Corporate Directors
| John Childs | Independent Director | Profile | |
| Robert Hugin | Independent Director | Profile | |
| Michael Heffernan | Lead Independent Director | Profile | |
| Julia Gregory | Independent Director | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biohaven Pharmaceutical Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biohaven Pharmaceutical. If investors know Biohaven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biohaven Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (9.37) | Return On Assets (1.19) | Return On Equity (2.65) |
The market value of Biohaven Pharmaceutical is measured differently than its book value, which is the value of Biohaven that is recorded on the company's balance sheet. Investors also form their own opinion of Biohaven Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biohaven Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biohaven Pharmaceutical's market value can be influenced by many factors that don't directly affect Biohaven Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biohaven Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biohaven Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biohaven Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.